Pliant Therapeutics (PLRX) announced the dosing of the first participant in the FORTIFY Phase 1b open-label indication expansion clinical trial of PLN-101095 in combination with pembrolizumab, in patients with immune checkpoint inhibitor -refractory advanced or metastatic solid tumors. PLN-101095 is an oral, small molecule, dual selective inhibitor of the integrins alphavbeta8 and alphavbeta1.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on PLRX:
- Pliant announces presentation of updated data from Phase 1 trial of PLN-101095
- Pliant Therapeutics Announces Board Retirements and Option Repricing
- Pliant Therapeutics Launches New $50 Million ATM Program
- Pliant Therapeutics files $300M mixed securities shelf
- Pliant Therapeutics price target lowered to $3 from $4 at Canaccord